PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25284689-3 2014 By using quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), we show that either ectopic expression of orphan nuclear receptor Nur77 or pharmacological activation of Nur77 by 6-mercaptopurine (6-MP) substantially inhibits ET-1 expression in human umbilical vein endothelial cells (HUVECs), under both basal and thrombin-stimulated conditions. Mercaptopurine 207-223 nuclear receptor subfamily 4 group A member 1 Homo sapiens 159-164 31273046-0 2019 Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling. Mercaptopurine 73-89 nuclear receptor subfamily 4 group A member 1 Homo sapiens 59-64 31273046-3 2019 Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients. Mercaptopurine 229-245 nuclear receptor subfamily 4 group A member 1 Homo sapiens 24-29 31273046-3 2019 Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients. Mercaptopurine 229-245 nuclear receptor subfamily 4 group A member 1 Homo sapiens 220-225 31273046-3 2019 Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients. Mercaptopurine 229-245 nuclear receptor subfamily 4 group A member 1 Homo sapiens 220-225 31273046-3 2019 Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients. Mercaptopurine 247-251 nuclear receptor subfamily 4 group A member 1 Homo sapiens 220-225 31273046-3 2019 Orphan nuclear receptor Nur77 is a key regulator of proliferation and inflammation in vascular cells, but its role in impaired BMP signalling and vascular remodelling in PAH is unknown.We hypothesised that activation of Nur77 by 6-mercaptopurine (6-MP) would improve PAH by inhibiting endothelial cell dysfunction and vascular remodelling.Nur77 expression is decreased in cultured pulmonary microvascular endothelial cells (MVECs) and lungs of PAH patients. Mercaptopurine 247-251 nuclear receptor subfamily 4 group A member 1 Homo sapiens 220-225 30123220-7 2018 Treatment of human moDCs with 6-mercaptopurine, an activator of Nur77, leads to diminished DC activation resulting in an impaired capacity to induce IFNgamma production by allogeneic T cells. Mercaptopurine 30-46 nuclear receptor subfamily 4 group A member 1 Homo sapiens 64-69 25284689-3 2014 By using quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), we show that either ectopic expression of orphan nuclear receptor Nur77 or pharmacological activation of Nur77 by 6-mercaptopurine (6-MP) substantially inhibits ET-1 expression in human umbilical vein endothelial cells (HUVECs), under both basal and thrombin-stimulated conditions. Mercaptopurine 207-223 nuclear receptor subfamily 4 group A member 1 Homo sapiens 198-203 16723716-7 2006 Finally, stretch-mediated proliferation was inhibited by 6-mercaptopurine, an agonist of TR3. Mercaptopurine 57-73 nuclear receptor subfamily 4 group A member 1 Homo sapiens 89-92 17146432-0 2007 6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1alpha resulting in new vessel formation. Mercaptopurine 0-16 nuclear receptor subfamily 4 group A member 1 Homo sapiens 34-39 20438716-10 2010 Finally, the expression of Nur77 increased along with that of p300, but decreased with induction of HDAC1 after treatment with epithelial growth factor, nerve growth factor, or 6-mercaptopurine, suggesting that the self-control of the acetylation status contributes to the transient induction of Nur77 protein. Mercaptopurine 177-193 nuclear receptor subfamily 4 group A member 1 Homo sapiens 27-32 15956351-3 2005 Recently, we found that the purine antimetabolite 6-Mercaptopurine (6-MP), which is widely used as an anti-neoplastic and anti-inflammatory drug, modulated the NR4A1-3 subfamily. Mercaptopurine 50-66 nuclear receptor subfamily 4 group A member 1 Homo sapiens 160-165 15956351-3 2005 Recently, we found that the purine antimetabolite 6-Mercaptopurine (6-MP), which is widely used as an anti-neoplastic and anti-inflammatory drug, modulated the NR4A1-3 subfamily. Mercaptopurine 68-72 nuclear receptor subfamily 4 group A member 1 Homo sapiens 160-165